Maybe the last two sentences are of interest. Whilst safety was obviously reviewed, they were maybe looking for signs of efficacy as well before continuing.
From the International Rett Syndrome Foundation:
"NNZ-2566 trial opens enrolment for second cohort
The Neuren-sponsored study of NNZ-2566 in Rett Syndrome has opened enrolment for its second treatment cohort. This Phase 2 clinical study entitled “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome” has been enrolling study participants since May 2013. In the first cohort, participants received either study medication at 35mg/kg b.i.d. or placebo (inactive study medication). For the second cohort, the dose of active study medication will increase to 70mg/kg b.i.d., and participants will be assigned to this dose or placebo. The study underwent two independent reviews by a Data Safety Monitoring Committee who recommended the ongoing conduct and escalation to the second cohort. Assessments reviewed include safety, autonomic measures (respiratory function, heart rhythm and rate), EEG abnormalities, study medication pharmacokinetics, behaviour, and global and functional measures."
http://www.rettsyndrome.org/irsflash/october-2013
Maybe the last two sentences are of interest. Whilst safety was...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |